ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Septerna (SEPN) pipeline and stated timing

Name in SEC filings: Septerna, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
SEP-479/data readoutStage not stated 20278-K ·

Source: ORION, orionbiotechai.com/company/SEPN, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/SEPN

Nearest upcoming stated timing: SEP-479 · Topline/data readout · Q1 2027

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
SEP-479Clinical resultsQ1 2027
“SAD / MAD Data Expected in Q1 2027”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

SEP-479Clinical resultslate 2026 or early 2027
“We anticipate reporting data from the trial in late 2026 or early 2027.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

SEP-479Clinical resultslate 2026 or early 2027
“data expected in late 2026 or early 2027.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

SEP-479Clinical resultslate 2026 or early 2027
“Septerna anticipates reporting data from the trial in late 2026 or early 2027.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

SEP-479Clinical resultsaround the end of 2026 or early 2027
“We anticipate announcing topline data from this Phase 1 clinical trial around the end of 2026 or early 2027.”

Filed · 10-K

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained founder-checked records

These dated records retain their original scope and check dates.

SEP-479 · report Phase 1 data from both the SAD and MAD cohorts

Record SEPN-P1 · Clinical results disclosure · Timing changed

Last checked: .

First stated window
“in late 2026 / early 2027”SEC Exhibit 99.1, filed
Disclosure date
None foundLast checked:

Initial statement

· Checked by founder · SEC Exhibit 99.1

Stated period: in late 2026 / early 2027

Anticipate topline data in late 2026 / early 2027

Statement retained

· Checked by founder · SEC Exhibit 99.1

Stated period: in late 2026 or early 2027

Septerna anticipates reporting data from the trial in late 2026 or early 2027.

Statement retained

· Checked by founder · SEC Form 10-Q

Stated period: late 2026 or early 2027

We anticipate reporting data from the trial in late 2026 or early 2027.

Statement retained

· Checked by founder · Company press release

Stated period: in the first quarter of 2027

As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.

Statement retained

· Checked by founder · SEC Form 10-Q

Stated period: in the first quarter of 2027

As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.

Context disclosure

· Checked by founder · SEC Form 10-Q

To fully characterize steady-state pharmacokinetics, dosing for the MAD cohorts will be extended to 14 days.

Part I, Item 2: Recent Developments, SEP-479 PTH1R Agonist Program; paragraph beginning Based on pharmacokinetic data (page 23)

Sources and scope

Company release: · Company original

Company release: · Company original

Company press release listing · checked

The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.

Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.

SEC filings searched through : and Ex-99.1 Jan–Aug 2026, Mar 31 and Jun 30 checked; Aug 10 states Q1 2027 with reason.

Company press releases checked : Press releases page checked on Oct 10, latest items reviewed.

Checked by founder: .

Corrections

· Corrected the April 13 event label to Statement retained; removed that equivalent expression from Wording changes. · The comparison treats late 2026 / early 2027 and late 2026 or early 2027 as equivalent timing alternatives. Original quotations are retained. · January 12 SEC Exhibit 99.1 and April 13 SEC Exhibit 99.1, retained in First stated and Changes.

· Added the August 10 10-Q sentence about extending MAD cohort dosing to 14 days as a Context disclosed row. · Founder requested the exact company quotation and original filing link. · https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm

· Updated the Changes explanation to: Status is set by founder review of the original filings. · The status is the founder-selected status retained in the reviewed record. · Founder correction request on 2026-10-10; the reviewed Timing changed status is retained.

Septerna (SEPN) — SEP-479 · report Phase 1 data from both the SAD and MAD cohorts: “in late 2026 / early 2027” (SEC Exhibit 99.1 2026-01-12); statement retained “in late 2026 or early 2027” (2026-04-13); statement retained “late 2026 or early 2027” (2026-05-11); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10). Status Timing changed, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1984086/000119312526009864/d81130dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm | https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0 | https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm

Retained program pages

Watch SEPN

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for SEPN. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See SEPN in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.